PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Fenoterol→

Fenoterol PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
13392-18-2
Molecular formula
C17H21NO4
Molecular weight
303.35 g/mol
Drug class
Short-acting beta-2 adrenergic receptor agonistbronchodilator
Mechanism of action
Activates beta-2 adrenergic receptors on bronchial smooth muscle, increases intracellular cyclic AMP and produces bronchodilation. At higher systemic exposure, beta-adrenergic effects may also influence cardiac rate and contractility.
Indications / reported uses
  • Relief of reversible bronchospasm in asthma and other obstructive airway diseases in countries where fenoterol inhalers remain authorised
  • Some formulations have historically been used for obstetric tocolysis; route-specific indications must not be transferred to inhaled products

Sources: NLM MeSH — Fenoterol · PubMed — Fenoterol pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Fenoterol PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Fenoterol Permitted Daily Exposure (PDE) report (the Fenoterol PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Fenoterol Occupational Exposure Limit (OEL) report (the Fenoterol OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.